OFFICIAL

Practition r's Docket No. 2001US405

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED **CENTRAL FAX CENTRE**

In re application of: LeGrow, et al.

FEB 0.3 2004

Application No.: 10/002,710

Group No.: 1615

Filed: 10/24/2001

LEAVE-ON COMPOSITIONS FOR PERSONAL CARE

Assistant Commissioner for Patent Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

CERTIFICATION UNDER 37 C.F.R. Sections 1.8(a) and 1.10* (When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

•	•									
[]	deposited with the United States Postal Service in a Patents, Washington, DC 20231.	an envelope addi	ressed to the Assistant Commissioner for							
	37 C.F.R. section 1.8(a)	37 C.F.R. section 1.10*								
[]	with sufficient postage as first class mail.	[]	as "Express Mail Post Office to Address" Mailing Label No (mandatory)							
/	TRA	NSMISSION								
M	transmitted by facsimile to the Patent and Trademark Office (703) 872-93.06									
Date:	2-3-04		1)500							
		Signat	Vicki SGRO							
	•	(type o	or print name of person certifying)							

*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).
"Since the filing of correspondence under (section) 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition. "Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Applicant: LeGrow, et al. Serial No. 10/002,710 Page 2

Dear Sir:

In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).

1.	Enclosures accompanying this Information Disclosure Statement are: 1a.					
2.	This information Disclosure Statement is filed under 37 CFR §1.97(b) with the filing of the U.S. patent application. Accordingly, no fee or §1.97(e) Statement is required.					
3.	This Information Disclosure Statement is filed under 37 CFR §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or §1.97(e) Statement is required.					
4.	This Information Disclosure Statement is filed under 37 CFR §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c) is to be charged to Deposit Account No. 03-2060.					
5	This Information Disclosure Statement is filed under 37 CFR §1.97(e) in that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is required.					
6.	This Information Disclosure Statement is filed in conjunction with a Request For Continued Examination. Accordingly, no fee or §1.97(e)					

Applicant: LeGrow, et al. Serial No. 10/002,710 Page 3

Statement is required.

- 7. The English language documents identified by reference in the TRANSLATION Section of the foreign patents list of the attached 1449 Form are believed to be a concise statement, or the equivalent or substantial equivalent to the foreign language documents cited in the attached 1449 Form.
- 8. In addition to the documents cited, the Office's attention is directed to the following copending U.S. Application Serial Number(s), copies of which are attached for the convenience of the Office:

Respectfully submitted,

Anthony A\Bisulca
Registration No. 40,913

CUSTOMER NO. 25,255

Clariant Corporation
Industrial Property Department
4000 Monroe Road
Charlotte, North Carolina 28205
Telephone: 704/331-7156
Facsimile: 704/331-7707

FORM FTO-1449 U.S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))			ATTY. DOCKET NO. 2001US405			SERTAL NO. 10/002,710					
			•			APPLICANT: Gary E. LEGRO FILING DATE: 10/24/01			w, et al.		
									GROUP: 1615		
			v.s.	PATEN	T DOCUMENTS						
Examiner Initial		Patent Number	Issue Date	Pate	ntee	Class	Subclass		Filing Date If Appropriate		
	AA	6,184,277	02/06/01	Bara		524	268				
	AB	6,489,274	12/03/02	LeGi	ow et al.	510	122				
	AC										
	AD						<u> </u>				
	AE						ļ				
	-		 								
		FORE	IGN PATENT OR	PUBL	ISHED FOREIGN	APPLICAT	ION				
		DOCUMENT NUMBER	PUB. DATE	coo	NTRY				TRANSLATION		
	BA	0 862 913	09/09/98	Eur	ope			*	See AA above		
	ВВ						<u> </u>				
	0	THER DOCUMENTS	(Including Au	tbor,	Title, Date	, Place of	Public	catio	on**)		
	CA								•		
	СВ										
EXAMINER				I	DATE CONSIDER	UED					